BDX Stock Forecast & Price Target

Becton Dickinson's financial performance demonstrates a robust growth trajectory, with total sales in FQ3'25 reaching $888 million, reflecting a year-over-year increase of 5.3%, driven by strong demand in Infusion Systems and Pharmacy Automation. The company's strategic focus, as highlighted by the BD 2025 initiative, has enabled continuous growth in its MedTech business, achieving over 6% growth annually alongside improving margins. Furthermore, key segments such as Peripheral Intervention and Biologics experienced significant sales increases of 4.5% and double-digit growth, respectively, underscoring the company's position as a leading provider in the medical products industry.

Becton Dickinson has reaffirmed a lowered organic revenue growth outlook of 3.0-3.5% for FY25, down from the previous forecast of 4.0-4.5%, reflecting ongoing challenges across its segments. In FQ3'25, the company reported $1.25 billion in sales, which signifies a year-over-year decline of 1.1% when excluding foreign exchange effects, largely driven by weakened demand in Biosciences and Diagnostic Solutions. Additionally, Becton Dickinson cited significant headwinds from volume-based procurement in China and reduced capital spending due to government funding cuts, particularly impacting its Biosciences and Diagnostic divisions.